export interface InsightDetailedSection {
  heading: string;
  body: string[];
  callout?: {
    title: string;
    text: string;
    metric?: string;
  };
  table?: {
    caption?: string;
    headers: string[];
    rows: string[][];
  };
}

export interface InsightItem {
  id: string;
  slug: string;
  category: 'blogs' | 'case-studies' | 'brochures' | 'news' | 'events';
  title: string;
  badge: string;
  date: string;
  readTime: string;
  author: {
    name: string;
    role: string;
    avatar?: string;
  };
  image: string;
  summary: string;
  keyTakeaways: string[];
  tags: string[];
  detailedContent: {
    subtitle: string;
    abstract: string;
    sections: InsightDetailedSection[];
    methodologyHighlights: string[];
    regulatoryImpact: string;
    citations?: string[];
  };
}

export const INSIGHT_TABS = [
  { id: 'blogs', label: 'Blogs & Articles', slug: 'blogs', icon: 'BookOpen', description: 'Scientific perspectives and process engineering insights from Lambda CDMO bioprocess specialists.' },
  { id: 'case-studies', label: 'Case Studies', slug: 'case-studies', icon: 'FileText', description: 'Empirical data and real-world outcomes from our development, scale-up, and clinical manufacturing programs.' },
  { id: 'brochures', label: 'Brochures', slug: 'brochures', icon: 'Download', description: 'Technical whitepapers, equipment specifications, and facility capability dossiers ready for review.' },
  { id: 'news', label: 'News & Press', slug: 'news', icon: 'Newspaper', description: 'Corporate announcements, regulatory inspection milestones, facility expansions, and industry partnerships.' },
  { id: 'events', label: 'Events & Webinars', slug: 'events', icon: 'Calendar', description: 'Upcoming scientific symposiums, regulatory masterclasses, partnering conferences, and live webinars.' },
] as const;

export const insightsData: Record<string, InsightItem[]> = {
  blogs: [
    {
      id: 'blog-1',
      slug: 'optimizing-cho-cell-line-selection',
      category: 'blogs',
      title: 'Optimizing CHO Cell Line Selection: High-Titre Clonal Stability & Targeted Glycosylation Profiles for Biosimilar mAbs',
      badge: 'Upstream Bioprocess',
      date: 'March 10, 2026',
      readTime: '7 min read',
      author: {
        name: 'Dr. Rajesh Varma',
        role: 'Head of Cell Line Development & Upstream Science',
      },
      image: '/images/insights/cho_cell_line.jpg',
      summary: 'Achieving consistent high-expression clonal lineages with tight critical quality attribute (CQA) matching requires methodical host vector engineering, high-throughput microfluidic single-cell deposition, and early fed-batch metabolic stress testing.',
      keyTakeaways: [
        'Demonstrated >6.5 g/L fed-batch titers sustained through 65 generations without chromosomal copy loss.',
        'Targeted fine-tuning of G0F/G1F galactose branching via trace manganese (Mn²⁺) and uridine supplementation.',
        'Zero genomic integration site rearrangements confirmed by long-read Oxford Nanopore sequencing.',
      ],
      tags: ['CHO-K1', 'Cell Line Engineering', 'Glycosylation CQAs', 'Biosimilars', 'Fed-Batch'],
      detailedContent: {
        subtitle: 'Engineering predictable mammalian cell factories for biosimilar monoclonal antibodies',
        abstract: 'In biosimilar and novel monoclonal antibody (mAb) manufacturing, clonal stability and targeted post-translational modifications—particularly N-linked glycosylation—represent pivotal critical quality attributes (CQAs). Here, we outline the Lambda CDMO platform strategy utilizing targeted epigenetic vectors in suspension-adapted CHO-K1 lines, coupled with imaged single-cell cloning and automated microbioreactor screening (Ambr 15), delivering predictable scale-up performance at 2000L commercial scale.',
        sections: [
          {
            heading: '1. Genomic Stability & Clonal Assurance',
            body: [
              'Regulatory authorities across the US FDA and EU EMA require rigorous documentation of clonality derived from a single progenitor cell (ICH Q5D). Our automated workflow utilizes high-contrast fluorescence imaging at 0h, 4h, and 24h post-deposition, achieving documented statistical assurance (>99.9% probability) of monoclonality.',
              'Clones undergo extended passage stress testing spanning 65 population doubling levels (PDLs), evaluating volumetric productivity, mRNA transcript integrity via droplet digital PCR (ddPCR), and gene locus stability. Top candidates retain over 92% of initial specific productivity (qP) across late-stage generations.',
            ],
            callout: {
              title: 'Key Bioprocess Metric',
              text: 'Top clonal candidates sustained specific productivities (qP) of 38-42 pg/cell/day across 14-day fed-batch bioreactor evaluations.',
              metric: '42 pg/cell/day',
            },
          },
          {
            heading: '2. Fine-Tuning Glycoform Ensembles to Match Reference Products',
            body: [
              'Glycosylation directly governs antibody effector functions (ADCC and CDC). In biosimilar development, matching the originator reference medicinal product (RMP) requires precise nutritional modulation of the Golgi nucleotide sugar precursor pools.',
              'By modulating trace transition metals (manganese chloride between 10-50 nM) and galactose precursors (uridine and D-galactose) in chemically defined feeds, we demonstrated precise control over the terminal galactosylation ratio (G0F vs G1F/G2F), matching innovator biosimilar windows within ±2.5% deviation.',
            ],
            table: {
              caption: 'Table 1: Glycan Distribution Modulation Under Controlled Feed Chemistries',
              headers: ['Parameter / Glycoform', 'Standard Feed', 'Optimized Lambda Feed', 'Reference Target Window'],
              rows: [
                ['G0F (Afucosylated Base)', '72.4%', '58.1%', '57.0% – 60.5%'],
                ['G1F (Mono-galactosylated)', '18.2%', '32.6%', '31.5% – 34.0%'],
                ['G2F (Di-galactosylated)', '3.1%', '6.8%', '6.2% – 7.5%'],
                ['Man-5 (High Mannose)', '4.2%', '1.9%', '< 2.5%'],
              ],
            },
          },
          {
            heading: '3. Seamless Scale-Up Transition into Single-Use Bioreactors',
            body: [
              'Predictable scale translation from 15 mL micro-scale vessels to 50L and 2000L single-use bioreactors (SUBs) relies on matched volumetric mass transfer coefficients (kLa) and equivalent power-per-unit-volume (P/V) parameters.',
              'The validated host platform exhibits robust tolerance to hydrodynamic shear and dissolved oxygen shifts, minimizing lactate accumulation (<1.2 g/L) and maintaining cell viability >90% through Day 14 harvest.',
            ],
          },
        ],
        methodologyHighlights: [
          'High-contrast digital brightfield/fluorescence monoclonality verification.',
          'Parallelized 24-way Ambr 15 microbioreactor screening for feed optimization.',
          'Intact mass spectrometry and 2-AB labeled HILIC-UPLC glycan profiling.',
          '65-generation generational stability study compliant with ICH Q5D guidelines.',
        ],
        regulatoryImpact: 'Satisfies ICH Q5A, Q5D, and Q6B guidance for master cell bank characterization, providing fully auditable origin records for global IND and BLA dossiers.',
      },
    },
    {
      id: 'blog-2',
      slug: 'overcoming-bispecific-antibody-aggregation',
      category: 'blogs',
      title: 'Overcoming Bispecific Antibody Aggregation: Multi-Modal Chromatography Strategies for Asymmetric Chain Assembly',
      badge: 'Downstream Purification',
      date: 'February 24, 2026',
      readTime: '6 min read',
      author: {
        name: 'Dr. Ananya Sen',
        role: 'Principal Downstream Purification Scientist',
      },
      image: '/images/insights/chromatography_purification.jpg',
      summary: 'Bispecific formats suffer from light-chain mispairing, half-molecules, and high-molecular-weight aggregates. Discover how mixed-mode resins and optimized pH gradients achieve >98.5% heterodimer purity.',
      keyTakeaways: [
        'Combined hydrophobic and electrostatic interaction resins eliminate homodimer species.',
        'High-molecular-weight aggregates (HMW) reduced from 14.2% post-Protein A to <0.8% post-polishing.',
        'Yield recovery maintained at 78% through a three-step orthogonal chromatography sequence.',
      ],
      tags: ['Bispecific Antibodies', 'Mixed-Mode Chromatography', 'HMW Aggregates', 'DSP', 'Purity'],
      detailedContent: {
        subtitle: 'Resolving product-related impurities in complex heterodimeric antibody formats',
        abstract: 'Bispecific antibodies (bsAbs) engineered through knobs-into-holes, CrossMAb, or dual-variable domain architectures frequently yield mispaired homodimers and high-molecular-weight (HMW) aggregates during expression. This article details a robust downstream purification sequence combining engineered affinity capture with multimodal anion exchange chromatography, resolving near-identical biophysical variants.',
        sections: [
          {
            heading: '1. The Challenge of Product-Related Variant Separation',
            body: [
              'Unlike standard IgG1 mAbs, bispecific variants present subtle differences in surface charge and hydrophobicity between correctly assembled heterodimers and mispaired homodimeric side products. Conventional Protein A chromatography captures all Fc-containing species indiscriminately.',
              'Consequently, downstream polishing must exploit subtle differential binding thermodynamics to separate heterodimers from structurally similar half-antibodies and non-functional homodimers.',
            ],
            callout: {
              title: 'Chromatographic Resolution',
              text: 'Capto MMC and Capto Adhere multi-modal resins demonstrated baseline resolution between correctly paired bsAb and homodimeric impurities with Delta-pI < 0.3.',
              metric: '>98.5% Purity',
            },
          },
          {
            heading: '2. Multi-Modal Anion Exchange (MM-AEX) Optimization',
            body: [
              'Utilizing multimodal ligands containing both quaternary amine and phenyl groups, we screened a comprehensive design-of-experiments (DoE) matrix of mobile phase conductivity and pH gradients. Running a shallow pH elution gradient from pH 7.8 down to pH 6.4 at 12 mS/cm achieved complete desorption of homodimer aggregates before heterodimer elution.',
              'This single step reduced aggregate levels from 11.8% to 0.6%, with an overall step recovery exceeding 84%.',
            ],
          },
          {
            heading: '3. Orthogonal SEC-MALS Verification',
            body: [
              'Size-Exclusion Chromatography combined with Multi-Angle Light Scattering (SEC-MALS) confirmed true absolute molecular weight corresponding to the 148.2 kDa heterodimer, ruling out reversible self-association or lingering soluble oligomers.',
            ],
          },
        ],
        methodologyHighlights: [
          'Affinity capture with engineered elution wash profiles.',
          'High-throughput resin screening on 96-well filter plates with Tecan automation.',
          'Preparative ÄKTA process chromatography with UV280 and inline conductivity monitoring.',
          'Orthogonal characterization via SEC-MALS, CE-SDS, and cIEF.',
        ],
        regulatoryImpact: 'Demonstrates robust clearance of product-related impurities per ICH Q6B, lowering immunogenicity risk in first-in-human clinical trials.',
      },
    },
    {
      id: 'blog-3',
      slug: 'advanced-lyophilization-cycle-design',
      category: 'blogs',
      title: 'Advanced Lyophilization Cycle Design: Overcoming Cake Collapse in High-Concentration Protein Formulations',
      badge: 'Formulation & DP',
      date: 'February 12, 2026',
      readTime: '8 min read',
      author: {
        name: 'Dr. Michael Thorne',
        role: 'Senior Formulation & Lyophilization Specialist',
      },
      image: '/images/insights/lyophilization_vials.jpg',
      summary: 'High-concentration biologics (>100 mg/mL) pose severe crystallization and collapse temperature (Tc) bottlenecks during freeze-drying. Learn our SMART freeze-drying cycle protocols.',
      keyTakeaways: [
        'Accurate glass transition (Tg\') and collapse temperature (Tc) determination via Freeze-Drying Microscopy (FDM).',
        'Optimized controlled nucleation reduced primary drying duration by 34% without micro-collapse.',
        'Residual moisture controlled to <1.2% w/w with complete reconstitution in under 90 seconds.',
      ],
      tags: ['Lyophilization', 'High-Concentration Biologics', 'Freeze-Drying Microscopy', 'Drug Product', 'Reconstitution'],
      detailedContent: {
        subtitle: 'Designing thermodynamically sound lyophilization cycles for sensitive biologic products',
        abstract: 'Formulating therapeutic proteins at elevated concentrations (>100 mg/mL) for subcutaneous delivery introduces critical thermodynamic constraints during freeze-drying. Low collapse temperatures (Tc) often necessitate protracted, costly cycles. We demonstrate a rational formulation design utilizing sucrose-histidine-polysorbate matrices with controlled ice nucleation, shortening cycles while safeguarding monomeric integrity.',
        sections: [
          {
            heading: '1. Thermal Characterization: DSC and FDM Analysis',
            body: [
              'Determining the exact glass transition temperature of the maximally freeze-concentrated solute (Tg\') and the micro-collapse onset temperature (Tc) is essential. Using differential scanning calorimetry (DSC) and freeze-drying microscopy (FDM), the critical product temperature for an anti-VEGF fusion protein was mapped to -31.4°C.',
              'Primary drying was engineered at a shelf temperature of -18°C with chamber pressure at 80 mTorr, keeping the sublimation ice front safely at -34°C, well below the structural collapse threshold.',
            ],
          },
          {
            heading: '2. Controlled Ice Nucleation Technology',
            body: [
              'Stochastic ice nucleation causes wide vial-to-vial variation in ice crystal morphology, leading to inconsistent sublimation resistance. By introducing depressurization-induced controlled nucleation at -5°C, uniform, large ice crystals formed across all batch vials.',
              'This increased pore diameter in the dried layer, reducing mass transfer resistance and cutting primary drying time from 58 hours down to 38 hours.',
            ],
            callout: {
              title: 'Process Optimization Result',
              text: 'Controlled nucleation eliminated batch variability, cutting primary drying duration by 20 hours while delivering pristine cake aesthetics.',
              metric: '-34% Cycle Time',
            },
          },
          {
            heading: '3. Long-Term Stability & Reconstitution Dynamics',
            body: [
              'Accelerated stability storage at 40°C/75% RH for 6 months confirmed zero aggregation increase (<0.2% by SEC) and no particulate formation. Karl Fischer coulometry verified residual moisture consistently below 1.1%.',
            ],
          },
        ],
        methodologyHighlights: [
          'Sub-ambient Differential Scanning Calorimetry (DSC).',
          'Lyostat freeze-drying microscopy with high-speed video capture.',
          'Manometric Temperature Measurement (MTM) for real-time sublimation monitoring.',
          'Karl Fischer coulometric moisture titration and Headspace Oxygen analysis.',
        ],
        regulatoryImpact: 'Provides comprehensive physicochemical data required under ICH Q1A(R2) stability and Q8 pharmaceutical development guidelines.',
      },
    },
    {
      id: 'blog-4',
      slug: 'physicochemical-characterization-ich-q6b',
      category: 'blogs',
      title: 'Physicochemical Characterization under ICH Q6B: Orthogonal SEC-MALS, Intact Mass LC-MS, and cIEF',
      badge: 'Analytical Sciences',
      date: 'January 28, 2026',
      readTime: '6 min read',
      author: {
        name: 'Dr. Neha Patel',
        role: 'Director of Analytical Characterization',
      },
      image: '/images/insights/mass_spectrometry_ich.jpg',
      summary: 'Regulatory filings demand orthogonal analytical packages to resolve high-order structure, charge heterogeneity, and post-translational variants with indisputable accuracy.',
      keyTakeaways: [
        'Complete primary sequence coverage (>99.5%) validated via high-resolution Orbitrap LC-MS/MS peptide mapping.',
        'Accurate quantification of acidic and basic charge variants using imaged capillary isoelectric focusing (icIEF).',
        'Orthogonal higher-order structure verification using Far/Near UV circular dichroism (CD) and HDX-MS.',
      ],
      tags: ['ICH Q6B', 'LC-MS/MS', 'icIEF', 'Charge Variants', 'Peptide Mapping', 'Comparability'],
      detailedContent: {
        subtitle: 'Comprehensive analytical workflows ensuring deep molecular understanding',
        abstract: 'Biologic therapeutics are heterogeneous macromolecular mixtures governed by primary sequence, secondary/tertiary folding, and dynamic post-translational modifications (PTMs). Under ICH Q6B, sponsors must establish rigorous specifications and orthogonal characterization profiles. This article details the analytical suite implemented at Lambda CDMO to de-risk biosimilar comparability and novel biologic filings.',
        sections: [
          {
            heading: '1. Intact Mass & Disulfide Bond Scrambling Analysis',
            body: [
              'Utilizing ultra-high resolution Q-TOF and Orbitrap mass spectrometers, intact and reduced deglycosylated monoclonal antibodies are resolved to within 2 ppm mass accuracy. This allows unambiguous identification of C-terminal lysine clipping, N-terminal pyroglutamate cyclization, and heavy/light chain pairing.',
              'Non-reduced peptide mapping with multi-enzyme digestion (trypsin, Asp-N) confirms 100% assignment of canonical intra- and inter-chain disulfide bonds without non-native shuffling.',
            ],
          },
          {
            heading: '2. Charge Heterogeneity Profiling via icIEF',
            body: [
              'Imaged capillary isoelectric focusing (icIEF) provides rapid, high-resolution separation of acidic variants (deamidation, sialylation) and basic variants (C-terminal lysine, oxidation). Across 10 commercial validation lots, our method demonstrated intra-day precision of <0.8% RSD for main peak quantification.',
            ],
          },
          {
            heading: '3. Higher-Order Structural (HOS) Comparability',
            body: [
              'Thermal stability was profiled using Differential Scanning Calorimetry (DSC), resolving distinct Fab, CH2, and CH3 domain unfolding transitions (Tm1 at 68.2°C, Tm2 at 82.5°C). Far-UV and Near-UV circular dichroism verified identical secondary beta-sheet content and tertiary aromatic microenvironments compared to innovator reference lots.',
            ],
          },
        ],
        methodologyHighlights: [
          'High-Resolution Accurate Mass (HRAM) Orbitrap LC-MS/MS analysis.',
          'Maurice icIEF for charge variant profiling with automated pI markers.',
          'MicroCal PEAQ-DSC differential scanning calorimetry.',
          'Sub-visible particulate testing via Micro-Flow Imaging (MFI) and Light Obscuration (HIAC).',
        ],
        regulatoryImpact: 'Fully compliant with ICH Q6B, FDA 21 CFR Part 11, and EMA guidelines on comparability of biotechnology-derived medicinal products.',
      },
    },
    {
      id: 'blog-5',
      slug: 'single-use-bioreactor-scale-up-50l-to-2000l',
      category: 'blogs',
      title: 'Single-Use Bioreactor Scale-Up (50L to 2000L): Shear Stress Mitigation & Mass Transfer Optimization',
      badge: 'Engineering & Upstream',
      date: 'January 14, 2026',
      readTime: '7 min read',
      author: {
        name: 'Arunav Sengupta',
        role: 'Senior Bioprocess Engineering Lead',
      },
      image: '/images/insights/single_use_bioreactor.jpg',
      summary: 'Scaling mammalian cell cultures across single-use bioreactor geometries requires rigorous matching of tip speed, hydrodynamic shear stress, and volumetric oxygen transfer (kLa).',
      keyTakeaways: [
        'Impeller tip speeds constrained under 1.8 m/s to prevent cell membrane microcarrier disruption.',
        'Sparger micro-hole design optimized to achieve kLa > 25 h⁻¹ while mitigating foaming and bubble burst shear.',
        'Zero drop in final harvest titer between 50L pilot scale (4.8 g/L) and 2000L commercial single-use trains (5.1 g/L).',
      ],
      tags: ['Single-Use Bioreactors', 'Bioprocess Scale-Up', 'kLa Mass Transfer', 'CFD Modeling', 'Upstream'],
      detailedContent: {
        subtitle: 'Engineering principles for flawless volumetric scaling in single-use platforms',
        abstract: 'Transitioning from benchtop seed trains to commercial 2000L single-use bioreactors (SUBs) is prone to mass transfer limitations, CO2 accumulation, and shear-induced cell lysis. Here, we present Computational Fluid Dynamics (CFD) modeling and empirical scale-up verification parameters that ensure linear titer and quality scaling across 50L, 200L, 500L, and 2000L SUB trains.',
        sections: [
          {
            heading: '1. Hydrodynamic Shear and Power-per-Unit-Volume (P/V)',
            body: [
              'Mammalian CHO cells lack rigid cell walls and are susceptible to shear stress near impeller blade tips and turbulent eddy micro-scales. We maintain constant P/V ratios between 20-35 W/m³ while ensuring maximum impeller tip speed remains below 1.8 m/s.',
              'CFD simulation of fluid flow patterns confirmed homogeneous mixing without dead zones, keeping blend times under 45 seconds at 2000L scale.',
            ],
          },
          {
            heading: '2. Oxygenation and Carbon Dioxide Stripping Dynamics',
            body: [
              'High-density cultures (>25 x 10⁶ cells/mL) consume oxygen rapidly while producing metabolic CO2 that can depress culture pH and alter protein sialylation. We implemented drilled-hole spargers engineered with 0.8 mm micro-orifices, optimizing gas bubble residence time to achieve kLa > 28 h⁻¹.',
              'Concurrent oxygen/air overlay sweeps maintain dissolved pCO2 below 90 mmHg throughout late-stage production days.',
            ],
          },
          {
            heading: '3. Commercial Lot Verification Data',
            body: [
              'Harvest data across three consecutive 2000L GMP demonstration batches showed identical product profiles to 50L development runs: cell viability stayed above 92% at Day 14 harvest, and final drug substance titers registered at 5.08 ± 0.12 g/L.',
            ],
          },
        ],
        methodologyHighlights: [
          'ANSYS Fluent CFD simulations of impeller hydrodynamic velocity fields.',
          'Dynamic gassing-out method for empirical kLa measurement.',
          'Inline Process Analytical Technology (PAT) using Hamilton optical DO and pH probes.',
          'Automated off-gas CO2 and O2 mass spectrometry analysis.',
        ],
        regulatoryImpact: 'Adheres to ICH Q8(R2) Quality by Design (QbD) principles for design space validation and process parameter verification.',
      },
    },
  ],

  'case-studies': [
    {
      id: 'cs-1',
      slug: 'ranibizumab-phase-3-biosimilar-clinical-supply',
      category: 'case-studies',
      title: 'Ranibizumab Phase III Biosimilar: Accelerated 14-Month Analytical Comparability, Clinical Formulation & Supply Campaign',
      badge: 'Biosimilar Commercialization',
      date: 'March 2026',
      readTime: '9 min read',
      author: {
        name: 'Dr. Suresh Chokshi',
        role: 'VP of Biologics Development & Manufacturing',
      },
      image: '/images/insights/ranibizumab_ophthalmic.jpg',
      summary: 'A global biopharmaceutical sponsor required expedited drug substance and drug product manufacturing for a Phase III ophthalmology clinical trial evaluating biosimilar Ranibizumab.',
      keyTakeaways: [
        'Gene-to-clinical supply achieved in 14 months, cutting standard industry timelines by 4 months.',
        'High-density E. coli refolding yield increased from 18% to 44% using optimized redox buffers.',
        'Passed rigorous double-blind Phase III clinical trial supply requirements across 42 clinical trial sites worldwide.',
      ],
      tags: ['Ranibizumab', 'Fab Fragment', 'E. coli Expression', 'Phase III Clinical', 'Ophthalmology'],
      detailedContent: {
        subtitle: 'Comprehensive CMC execution delivering sterile ophthalmic clinical batches under compressed timelines',
        abstract: 'Ranibizumab is an affinity-matured anti-VEGF-A Fab fragment expressed in E. coli, indicated for neovascular age-related macular degeneration. The sponsor required complete process development, analytical comparability with Lucentis®, and aseptic fill-finish into single-dose ophthalmic vials. Lambda CDMO engineered an intensified inclusion body refolding protocol and validated sterile fill-finish under closed barrier isolators, delivering clinical supplies on an accelerated 14-month critical path.',
        sections: [
          {
            heading: '1. Upstream Microbial Fermentation & Inclusion Body Recovery',
            body: [
              'High-cell-density fed-batch fermentation of recombinant E. coli BL21(DE3) was scaled to 300L. By applying an exponential feeding algorithm coupled with sorbitol-assisted low-temperature induction (24°C), inclusion body formation reached 14.8 g dry cell weight per liter.',
              'Cells were harvested via continuous disc-stack centrifugation and lysed with high-pressure homogenization at 12,000 psi across 3 passes, achieving >98% cell disruption.',
            ],
          },
          {
            heading: '2. High-Yield Oxidative Refolding and Purification',
            body: [
              'Conventional Fab refolding suffers from improper intramolecular disulfide pairing and heavy aggregation. Our team engineered an optimized redox folding matrix featuring reduced/oxidized glutathione (GSH/GSSG ratio 4:1) with 0.8 M L-arginine as an aggregation suppressor.',
              'Refolding efficiency surged from an initial 18% to 44.2%. Subsequent capture via cation exchange chromatography followed by hydrophobic interaction chromatography (HIC) removed misfolded species and residual host cell proteins down to <5 ppm.',
            ],
            callout: {
              title: 'Refolding Breakthrough',
              text: 'The optimized redox refolding cocktail elevated properly folded Fab yield from 18% to 44.2%, doubling overall drug substance output per fermentation batch.',
              metric: '44.2% Refolding Yield',
            },
          },
          {
            heading: '3. Aseptic Ophthalmic Fill-Finish & Endotoxin Clearance',
            body: [
              'Intravitreal therapeutics mandate ultra-stringent particulate and endotoxin limits (<0.5 EU/mL). Drug product was sterile-filtered and filled into 0.05 mL low-dead-volume glass vials using our automated robotic barrier isolator line, registering 100% sterile fill integrity and undetectable particulates >10 μm.',
            ],
          },
        ],
        methodologyHighlights: [
          'Exponential feed fermentation with dissolved oxygen feedback control.',
          'High-throughput refolding screen using 96-well microplate spectrometry.',
          'Cation exchange and mixed-mode chromatographic purification.',
          'Ophthalmic Grade A isolator filling with automated 100% weight check.',
        ],
        regulatoryImpact: 'Enabled immediate clearance of Phase III IND and CTA applications across US FDA, EMA, and CDSCO regulatory jurisdictions.',
      },
    },
    {
      id: 'cs-2',
      slug: 'denosumab-high-yield-cho-titer-optimization',
      category: 'case-studies',
      title: 'Denosumab High-Yield CHO Platform: 6.8 g/L Titer Optimization with Critical Quality Attribute (CQA) Matching',
      badge: 'Monoclonal Antibodies',
      date: 'February 2026',
      readTime: '8 min read',
      author: {
        name: 'Dr. Priya Nambiar',
        role: 'Director of Process Development',
      },
      image: '/images/insights/denosumab_bioreactor.jpg',
      summary: 'Achieving biosimilar fingerprint matching for fully human anti-RANKL mAb Denosumab while dramatically boosting fed-batch titers in a commercial-ready CHO-S host cell platform.',
      keyTakeaways: [
        'Volumetric titer elevated from 2.4 g/L to 6.8 g/L via targeted nutrient feed balance.',
        'Targeted afucosylation matched reference product window (4.2% – 5.8%) without genetic knockouts.',
        'Zero aggregate increase through 3 cycles of freeze-thaw at 50L bulk drug substance scale.',
      ],
      tags: ['Denosumab', 'CHO-S', 'Anti-RANKL', 'CQA Matching', 'Titer Optimization'],
      detailedContent: {
        subtitle: 'Balancing extreme volumetric productivity with strict biosimilar CQA tolerance limits',
        abstract: 'Denosumab is an IgG2 monoclonal antibody that binds human RANKL to treat osteoporosis and bone metastases. The sponsor sought to replace an inefficient 2.4 g/L process with a high-titer manufacturing process while matching the innovator (Prolia®/Xgeva®) fingerprint in charge variant distribution and oligosaccharide profile. Lambda CDMO attained 6.8 g/L through multi-factorial feed optimization while maintaining perfect CQA alignment.',
        sections: [
          {
            heading: '1. Upstream Nutrient Balance & Process Intensification',
            body: [
              'Using high-throughput microbioreactor DoE studies, we identified critical metabolic shifts associated with excessive ammonium accumulation. Implementing a dynamic glucose setpoint (1.5 - 2.5 g/L) coupled with concentrated amino acid feeding extended culture viability past 16 days.',
              'Specific productivity reached 46 pg/cell/day, culminating in harvest titers of 6.82 g/L at day 15.',
            ],
          },
          {
            heading: '2. Precise CQA Fingerprinting',
            body: [
              'IgG2 antibodies exhibit complex disulfide isoform heterogeneity (IgG2-A, IgG2-B, and IgG2-A/B intermediates). Controlled redox conditioning during harvest clarification shifted the isoform distribution to match the commercial reference standard within ±1.5%.',
              'Charge profile analysis via cIEF confirmed 64.2% main peak, 22.8% acidic, and 13.0% basic variants, completely within reference medicinal product release specifications.',
            ],
            callout: {
              title: 'Titer Escalation',
              text: 'Optimized metabolic feeding increased volumetric harvest titer from 2.4 g/L to 6.8 g/L, nearly tripling batch yield per 2000L run.',
              metric: '6.8 g/L Titer',
            },
          },
        ],
        methodologyHighlights: [
          'High-density fed-batch fermentation in single-use bioreactors.',
          'Hydrophobic Interaction Chromatography (HIC) for IgG2 structural isoform separation.',
          'High-resolution intact mass and peptide mapping by LC-MS/MS.',
        ],
        regulatoryImpact: 'Provided ironclad analytical biosimilarity dossier supporting comparative clinical trial authorization in the US and Europe.',
      },
    },
    {
      id: 'cs-3',
      slug: 'bispecific-bite-downstream-recovery-purity',
      category: 'case-studies',
      title: 'Bispecific T-Cell Engager (BiTE) Downstream Recovery: Resolving Light-Chain Mispairing to Achieve >98.5% Purity',
      badge: 'Next-Gen Modalities',
      date: 'January 2026',
      readTime: '7 min read',
      author: {
        name: 'Dr. Ananya Sen',
        role: 'Principal Downstream Purification Scientist',
      },
      image: '/images/insights/bite_purification.jpg',
      summary: 'Resolving product-related homodimer and light chain mispairings in an asymmetric CD3 x Tumor Antigen bispecific construct, scaling from bench to 500L pilot manufacturing.',
      keyTakeaways: [
        'Separated near-identical homodimer species differing by only 0.2 pI units.',
        'High-recovery multi-modal chromatography step achieved 82% target molecule yield.',
        'Final drug substance exhibited monomeric purity >98.8% with undetectable high-molecular-weight aggregates.',
      ],
      tags: ['BiTE', 'Bispecifics', 'Downstream Processing', 'Impurity Clearance', 'Pilot Scale'],
      detailedContent: {
        subtitle: 'Innovative chromatographic separation of closely related structural isoforms',
        abstract: 'Asymmetric bispecific constructs engineered for immuno-oncology T-cell redirection frequently express a mixture of desired heterodimers, homodimers, and free heavy/light chain intermediates. We designed an advanced downstream purification platform that resolved structural mispairs, yielding clinical-grade material with >98.5% monomeric purity.',
        sections: [
          {
            heading: '1. Screening Multimodal Chromatography Ligands',
            body: [
              'Because Protein A captures both heterodimers and Fc-homodimers equally, we screened mixed-mode ion-exchange and hydrophobic interaction resins across 96-well plates. Capto MMC demonstrated exceptional selectivity when operated in bind-and-elute mode with a dual pH and salt step-gradient.',
              'Homodimer contamination was depleted from 16.4% in the crude harvest down to 0.4% in the eluted peak pool.',
            ],
          },
          {
            heading: '2. 500L Scale Demonstration',
            body: [
              'The process was directly transferred to our 500L pilot manufacturing suite. Chromatographic elution profiles and recovery yields matched benchtop scale within ±3%, proving linear scalability and process robustness.',
            ],
          },
        ],
        methodologyHighlights: [
          'Automated micro-scale resin selectivity screening.',
          'Preparative chromatography with inline UV, pH, and conductivity gradient control.',
          'Analytical SEC-MALS and non-reduced CE-SDS characterization.',
        ],
        regulatoryImpact: 'Delivered toxicology and Phase I clinical drug substance meeting all FDA requirements for adventitious agent and impurity limits.',
      },
    },
    {
      id: 'cs-4',
      slug: 'rapid-tech-transfer-adc-containment-100l',
      category: 'case-studies',
      title: 'Rapid Tech Transfer of an Antibody-Drug Conjugate (ADC): Scaled to 100L Under Containment in Grade C Cleanrooms',
      badge: 'ADC Bioconjugation',
      date: 'December 2025',
      readTime: '8 min read',
      author: {
        name: 'Dr. Marcus Vance',
        role: 'Head of Conjugation Chemistry & High-Potency Operations',
      },
      image: '/images/insights/adc_containment.jpg',
      summary: 'Executing safe handling, stoichiometric reduction, and payload conjugation of a potent monomethyl auristatin E (MMAE) cytotoxin with tight Drug-to-Antibody Ratio (DAR) control.',
      keyTakeaways: [
        'Conjugation process scaled safely in negative-pressure high-containment isolators (OEL < 10 ng/m³).',
        'Target DAR of 4.0 ± 0.2 consistently achieved across 4 consecutive batches.',
        'Free residual drug-linker payload depleted to <0.1% via single-pass tangential flow filtration (TFF).',
      ],
      tags: ['ADCs', 'MMAE', 'DAR Control', 'High Potency Containment', 'Technology Transfer'],
      detailedContent: {
        subtitle: 'Precision chemical conjugation of cytotoxic payloads to targeted monoclonal antibodies',
        abstract: 'Antibody-Drug Conjugates (ADCs) combine biological specificity with potent small-molecule cytotoxins, requiring specialized high-potency containment (SafeBridge Category 4) and delicate conjugation chemistry. Lambda CDMO successfully transferred, optimized, and manufactured an interchain cysteine-conjugated ADC at 100L batch scale within 6 months.',
        sections: [
          {
            heading: '1. Engineering Controls & Safe Handling of Potent Payloads',
            body: [
              'Handling payloads with Occupational Exposure Limits (OEL) below 10 ng/m³ demands strict isolator containment. Our automated closed-system conjugation vessel operates under continuous negative pressure with HEPA filtration and integrated CIP/SIP sanitization.',
              'Air monitoring throughout raw material dispensing and reaction execution verified zero containment breaches.',
            ],
          },
          {
            heading: '2. Precise Drug-to-Antibody Ratio (DAR) Control',
            body: [
              'Partial reduction of interchain disulfide bonds using tris(2-carboxyethyl)phosphine (TCEP) was monitored via inline RP-HPLC. Stoichiometric addition of maleimide-caproyl-valine-citrulline-PABC-MMAE payload achieved a narrow DAR distribution centered at 4.05, matching clinical potency specifications.',
            ],
          },
        ],
        methodologyHighlights: [
          'High-containment isolator manipulation of high-potency toxins.',
          'HIC and RP-HPLC for real-time DAR quantification.',
          'Ultrafiltration/diafiltration (UF/DF) with regenerated cellulose membranes for payload clearance.',
        ],
        regulatoryImpact: 'Fully compliant with cGMP regulations and international containment standards for cytotoxic biologic drug substance production.',
      },
    },
    {
      id: 'cs-5',
      slug: 'host-cell-protein-dna-clearance-commercial-ppq',
      category: 'case-studies',
      title: 'Host-Cell Protein (HCP) & DNA Clearance: Validated Clearance in 3 Commercial Process Validation (PPQ) Lots',
      badge: 'Process Validation',
      date: 'November 2025',
      readTime: '7 min read',
      author: {
        name: 'Dr. Neha Patel',
        role: 'Director of Analytical Characterization',
      },
      image: '/images/insights/hcp_dna_testing.jpg',
      summary: 'Demonstrating total clearance of process-related residual host cell proteins (HCP) and host cell DNA (HCD) across three commercial-scale 2,000L Process Performance Qualification (PPQ) runs.',
      keyTakeaways: [
        'Total HCP reduced from >250,000 ng/mg in clarified harvest to <1.8 ng/mg in purified drug substance.',
        'Residual host cell DNA measured at <0.8 pg/mg, far below WHO and FDA thresholds (<10 ng/dose).',
        'Demonstrated >12.4 log10 overall retrovirus-like particle (RVLP) clearance across orthogonal viral clearance steps.',
      ],
      tags: ['Process Validation', 'PPQ', 'HCP Clearance', 'Host Cell DNA', 'Viral Clearance'],
      detailedContent: {
        subtitle: 'Rigorous validation data proving impurity depletion across commercial-scale manufacturing runs',
        abstract: 'Process-related impurities such as residual host-cell proteins (HCP) and host-cell DNA (HCD) carry substantial immunogenicity and oncogenicity risks. For a commercial monoclonal antibody program, Lambda CDMO validated impurity clearance across three consecutive 2,000L PPQ campaigns, achieving industry-leading purity benchmarks required for commercial BLA filing.',
        sections: [
          {
            heading: '1. Multi-Dimensional Orthogonal Clearance Sequence',
            body: [
              'Clarified harvest was processed through Protein A capture, low-pH viral inactivation (pH 3.55 for 60 min), cation exchange chromatography (CEX), and flow-through anion exchange membrane chromatography (AEX).',
              'The AEX polishing step alone provided >3.5 log10 removal of residual DNA and acidic host-cell protein variants.',
            ],
            table: {
              caption: 'Table 2: Impurity Clearance Profile Across Commercial PPQ Batches',
              headers: ['Step / Parameter', 'Harvest Clarified', 'Post-Protein A', 'Post-CEX', 'Final Drug Substance'],
              rows: [
                ['Residual HCP (ELISA)', '284,000 ppm', '1,420 ppm', '34 ppm', '< 1.8 ppm'],
                ['Residual Host DNA (qPCR)', '12,500 pg/mg', '82 pg/mg', '4.1 pg/mg', '< 0.8 pg/mg'],
                ['Monomeric Purity (SEC)', '86.4%', '96.2%', '98.9%', '99.4%'],
              ],
            },
          },
          {
            heading: '2. Commercial BLA Submission Readiness',
            body: [
              'Statistical process capability indices (Cpk > 1.67) demonstrated exceptional process reproducibility, satisfying FDA and EMA commercial readiness standards.',
            ],
          },
        ],
        methodologyHighlights: [
          'Commercial CHO HCP ELISA with coverage verification by 2D Western Blotting.',
          'Quant-iT PicoGreen and TaqMan quantitative PCR for residual host cell DNA.',
          'Viral clearance validation using model retroviruses (X-MuLV) and parvoviruses (MVM).',
        ],
        regulatoryImpact: 'Provides pivotal Section 3.2.S.2.5 process validation data for commercial BLA and MAA filings.',
      },
    },
  ],

  brochures: [
    {
      id: 'brochure-1',
      slug: 'lambda-cdmo-capabilities-master-compendium',
      category: 'brochures',
      title: 'Lambda CDMO Capabilities Master Compendium 2026: Gene-to-Clinic Biologics Development & cGMP Manufacturing',
      badge: 'Comprehensive Dossier',
      date: '2026 Edition',
      readTime: 'Downloadable PDF • 32 Pages',
      author: {
        name: 'Lambda CDMO Engineering & Operations',
        role: 'Ahmedabad Biologics Campus',
      },
      image: '/images/insights/cdmo_facility_exterior.jpg',
      summary: 'The definitive guide to Lambda CDMO’s integrated biologics infrastructure, detailing cleanroom classifications, bioreactor trains (50L–2000L), analytical suites, and regulatory compliance.',
      keyTakeaways: [
        'Complete overview of our 20,000 sqm purpose-built biologics facility in Ahmedabad, India.',
        'Technical specifications for mammalian cell line development, microbial fermentation, and single-use processing.',
        'Comprehensive breakdown of our Grade A barrier isolator fill-finish capabilities for liquid and lyophilized formats.',
      ],
      tags: ['Facility Overview', 'Capabilities', 'Bioreactors', 'Fill-Finish', 'Specifications'],
      detailedContent: {
        subtitle: 'Your complete reference for integrated biologics development and clinical manufacturing',
        abstract: 'This comprehensive compendium details our state-of-the-art biopharmaceutical campus, designed in compliance with US FDA, EU EMA, and WHO cGMP guidelines. Discover how our end-to-end integration—from cell line generation through aseptic fill-finish—accelerates clinical timelines while minimizing technology transfer friction.',
        sections: [
          {
            heading: '1. Upstream & Downstream Processing Specifications',
            body: [
              'Detailed layout of our dual upstream cleanroom suites featuring Thermo Fisher HyPerforma and Cytiva single-use bioreactors from 50L to 2,000L capacity.',
              'Includes downstream purification suites equipped with automated ÄKTA process skids, ultrafiltration/diafiltration (UF/DF) systems, and multi-use chromatography columns up to 1,000 mm diameter.',
            ],
          },
          {
            heading: '2. Quality Management System & Regulatory Pedigree',
            body: [
              'Built on Lambda Therapeutic Research’s 25-year legacy of clinical excellence, our quality management system enforces 21 CFR Part 11 electronic data integrity, full supply chain traceability, and paperless MES execution.',
            ],
          },
        ],
        methodologyHighlights: [
          'Full equipment capacity tables and cleanroom HVAC schematics.',
          'Standard timeline benchmarks from cDNA sequence to RCB release (14 weeks).',
          'Analytical testing menu covering identity, purity, potency, and safety.',
        ],
        regulatoryImpact: 'Serves as an essential preliminary dossier for sponsor Quality Audits and Qualified Person (QP) inspections.',
      },
    },
    {
      id: 'brochure-2',
      slug: 'analytical-sciences-physicochemical-characterization-dossier',
      category: 'brochures',
      title: 'Analytical Sciences & Physicochemical Characterization Dossier: ICH Q6B & Q14 Compliance Menu',
      badge: 'Analytical Menu',
      date: '2026 Edition',
      readTime: 'Technical Guide • 24 Pages',
      author: {
        name: 'Analytical Development Sciences',
        role: 'Lambda Quality Control Team',
      },
      image: '/images/insights/analytical_suite_overview.jpg',
      summary: 'A detailed catalog of our high-resolution analytical instrument fleet, validated assay menus, stability testing chambers, and biological potency testing capabilities.',
      keyTakeaways: [
        'Full inventory of mass spectrometers (Q-TOF, Orbitrap LC-MS), UPLCs, and capillary electrophoresis platforms.',
        'Complete method validation protocols compliant with ICH Q2(R2) and the newly implemented ICH Q14 guidelines.',
        'In vitro cell-based bioassay and SPR/BLI surface plasmon resonance binding kinetic packages.',
      ],
      tags: ['Analytical Testing', 'ICH Q6B', 'Mass Spectrometry', 'Bioassays', 'Stability Testing'],
      detailedContent: {
        subtitle: 'In-depth testing specifications supporting regulatory release and comparability',
        abstract: 'Characterizing modern biologics requires unprecedented analytical resolution. This dossier details the complete testing capabilities of Lambda CDMO’s analytical laboratories, encompassing release testing, in-process control (IPC), stability storage, and deep structural characterization.',
        sections: [
          {
            heading: '1. Physicochemical Testing Fleet',
            body: [
              'Covers SEC-MALS, RP-UPLC, HILIC, IEX, CE-SDS (reducing and non-reducing), Maurice icIEF, and HIAC sub-visible particle counters.',
            ],
          },
          {
            heading: '2. Potency, Binding & Bioassays',
            body: [
              'Features SPR (Biacore 8K) for target antigen affinity, FcRn/FcγR binding, and cell-based reporter gene assays for ADCC/CDC characterization.',
            ],
          },
        ],
        methodologyHighlights: [
          'ICH-compliant stability storage chambers (25°C/60% RH, 40°C/75% RH, 5°C, -20°C, -80°C).',
          'Photostability testing per ICH Q1B.',
        ],
        regulatoryImpact: 'Enables rapid creation of Module 3.2.S.4 and 3.2.P.5 analytical documentation.',
      },
    },
    {
      id: 'brochure-3',
      slug: 'single-use-bioreactor-platform-specifications',
      category: 'brochures',
      title: 'Single-Use Bioreactor (SUB) Platform Specifications: 50L, 200L, 500L & 2000L Processing Trains',
      badge: 'Upstream Specs',
      date: '2026 Edition',
      readTime: 'Engineering Spec • 18 Pages',
      author: {
        name: 'Bioprocess Engineering Group',
        role: 'Manufacturing Sciences & Technology (MSAT)',
      },
      image: '/images/insights/sub_bioreactor_train.png',
      summary: 'Engineering parameters, fluid mixing dynamics, sparger configurations, and extractable/leachable (E&L) certification records for our mammalian bioreactor trains.',
      keyTakeaways: [
        'Turn-down ratios and minimum working volumes across 50L (15L min), 200L (50L min), and 2000L (500L min) vessels.',
        'Comprehensive USP <665> and BPOG extractable/leachable compliance documentation.',
        'Automated gaseous mass flow controllers supporting pure oxygen enrichment up to 50 SLPM.',
      ],
      tags: ['Single-Use Bioreactors', 'Upstream Specs', 'Extractables & Leachables', 'Engineering', 'MSAT'],
      detailedContent: {
        subtitle: 'Technical specifications for single-use cell culture vessels and seed trains',
        abstract: 'This document provides complete engineering diagrams, sparger geometry options, impeller dimensions, and automation software integration details for Lambda CDMO’s single-use mammalian cell culture bioreactors.',
        sections: [
          {
            heading: '1. Vessel Geometries and Aeration Capacities',
            body: [
              'Detailed specifications for micro-spargers, open-pipe spargers, and dual-impeller mixing shafts designed to eliminate shear gradients in sensitive mammalian and fusion-protein cultures.',
            ],
          },
        ],
        methodologyHighlights: [
          'Allen-Bradley FactoryTalk Batch automated control system.',
          'Integrated single-use sterile sampling manifolds with zero contamination risk.',
        ],
        regulatoryImpact: 'Full compliance with ASME BPE guidelines and global sanitary design requirements.',
      },
    },
    {
      id: 'brochure-4',
      slug: 'aseptic-fill-finish-barrier-isolator-whitepaper',
      category: 'brochures',
      title: 'Aseptic Fill-Finish & Barrier Isolator Technical Whitepaper: Zero Contamination Vials & Pre-Filled Syringes',
      badge: 'Drug Product Whitepaper',
      date: '2026 Edition',
      readTime: 'Whitepaper • 20 Pages',
      author: {
        name: 'Aseptic Processing Operations',
        role: 'Fill-Finish Manufacturing Division',
      },
      image: '/images/insights/robotic_fill_finish.png',
      summary: 'Technical review of our Grade A closed-barrier isolator filling line with 100% in-process checkweighing, nest-based syringe filling, and automated vaporized hydrogen peroxide (VHP) cycles.',
      keyTakeaways: [
        'Zero human intervention within the Grade A zone during active filling operations.',
        'Flexible processing for 2R–50R glass vials and 0.5 mL–3 mL pre-filled syringes (PFS).',
        'Peristaltic and rotary piston dosing pumps ensuring fill accuracy within ±0.5% at volumes down to 0.1 mL.',
      ],
      tags: ['Fill-Finish', 'Aseptic Processing', 'Barrier Isolator', 'Pre-Filled Syringes', 'VHP Decontamination'],
      detailedContent: {
        subtitle: 'Ensuring absolute sterility and precision dosing for injectable biologics',
        abstract: 'Injectable biologics require pristine sterility assurance levels (SAL 10⁻⁶). This whitepaper outlines our closed-barrier isolator filling architecture, engineered to prevent microbial and particulate ingress during high-value clinical and commercial drug product manufacturing.',
        sections: [
          {
            heading: '1. Barrier Isolator and VHP Decontamination',
            body: [
              'Continuous laminar airflow (0.45 m/s ± 20%) maintained under positive differential pressure (+30 Pa) with automated VHP biodecontamination delivering documented 6-log Geobacillus stearothermophilus spore reduction.',
            ],
          },
        ],
        methodologyHighlights: [
          'Non-destructive 100% in-process tare-gross checkweighing.',
          'Restricted Access Barrier Systems (RABS) and fully enclosed Gloveless Robotic options.',
        ],
        regulatoryImpact: 'Compliant with Annex 1 revision (Manufacture of Sterile Medicinal Products) and FDA Aseptic Guidance.',
      },
    },
    {
      id: 'brochure-5',
      slug: 'global-regulatory-cmc-roadmap-ind-bla',
      category: 'brochures',
      title: 'Global Regulatory CMC Roadmap: Strategic IND, IMPD & BLA Dossier Packages for FDA, EMA & PMDA',
      badge: 'Regulatory Strategy',
      date: '2026 Edition',
      readTime: 'Regulatory Dossier • 22 Pages',
      author: {
        name: 'Regulatory Affairs & Compliance',
        role: 'Lambda Global Regulatory Advisory',
      },
      image: '/images/insights/regulatory_cmc_roadmap.png',
      summary: 'How Lambda CDMO guides sponsors through Module 3 CMC authoring, analytical comparability protocols, agency scientific advice meetings, and rapid regulatory clearance.',
      keyTakeaways: [
        'Turnkey eCTD Module 3 authoring for investigational (IND/IMPD) and marketing (BLA/MAA) submissions.',
        'Comprehensive formal briefing package preparation for FDA Type B/C and EMA Scientific Advice meetings.',
        'Proven track record supporting first-pass approvals across North America, Europe, and Asia-Pacific.',
      ],
      tags: ['Regulatory CMC', 'eCTD Module 3', 'IND Filing', 'BLA Submission', 'FDA / EMA'],
      detailedContent: {
        subtitle: 'De-risking regulatory interactions through scientifically grounded CMC documentation',
        abstract: 'This roadmap provides sponsors with a step-by-step framework for navigating global CMC regulatory hurdles. From raw material qualification to process validation and stability protocols, our regulatory team ensures your dossier withstands rigorous agency scrutiny.',
        sections: [
          {
            heading: '1. Integrated Quality-by-Design (QbD) CMC Packages',
            body: [
              'Structured mapping of Critical Quality Attributes (CQAs), Critical Process Parameters (CPPs), and control strategies within the standard Common Technical Document (CTD) format.',
            ],
          },
        ],
        methodologyHighlights: [
          'Gap analysis against latest FDA and EMA biologics guidance.',
          'Audit-ready analytical method verification dossiers.',
        ],
        regulatoryImpact: 'Accelerates regulatory review cycles, preventing costly clinical hold delays.',
      },
    },
  ],

  news: [
    {
      id: 'news-1',
      slug: 'regulatory-cgmp-compliance-inspection-zero-483',
      category: 'news',
      title: 'Lambda CDMO Completes Multi-Agency Regulatory cGMP Compliance Inspection with Zero 483 Observations',
      badge: 'Regulatory Milestone',
      date: 'March 02, 2026',
      readTime: '4 min read',
      author: {
        name: 'Corporate Communications',
        role: 'Lambda CDMO Quality Assurance',
      },
      image: '/images/insights/cgmp_audit_inspection.png',
      summary: 'Lambda CDMO has successfully concluded a rigorous multi-agency regulatory cGMP audit covering its biologics development and commercial manufacturing campus, receiving zero Form 483 observations.',
      keyTakeaways: [
        'Zero Form 483 observations received across comprehensive 5-day facility audit.',
        'Audit inspected cell banking, upstream bioreactor suites, downstream purification, and QC laboratories.',
        'Validates our unified quality management system and electronic data integrity architecture.',
      ],
      tags: ['cGMP Inspection', 'Zero 483', 'Quality Systems', 'FDA Compliance', 'Corporate News'],
      detailedContent: {
        subtitle: 'Uncompromising adherence to global standards verified by independent regulatory scrutiny',
        abstract: 'Ahmedabad, India — Lambda CDMO today announced the successful conclusion of a comprehensive cGMP inspection conducted by international regulatory authorities. The inspection evaluated facilities, equipment qualification, analytical QC data integrity, personnel training, and commercial-scale batch records, culminating in zero adverse observations.',
        sections: [
          {
            heading: '1. Scope of the Facility Audit',
            body: [
              'The five-day inspection encompassed every facet of the Ahmedabad campus, including the Grade A/B aseptic fill-finish suites, 50L–2000L single-use bioreactor bays, automated QC testing suites, and cryogenic cell bank repositories.',
              'Auditors reviewed electronic audit trails across all computerized chromatography and spectrophotometric systems, affirming complete adherence to 21 CFR Part 11 and ALCOA+ data integrity principles.',
            ],
          },
          {
            heading: '2. Executive Commentary',
            body: [
              '“Achieving a flawless inspection outcome reflects the unwavering dedication of our scientific and quality teams,” said the Managing Director. “This milestone reinforces Lambda CDMO’s position as a premier global partner for clinical and commercial biologics programs.”',
            ],
          },
        ],
        methodologyHighlights: [
          'Full paperless Manufacturing Execution System (MES) verification.',
          'Review of 12 commercial batch records and continuous environmental monitoring logs.',
        ],
        regulatoryImpact: 'Reaffirms commercial manufacturing readiness for international sponsors launching clinical and market supply.',
      },
    },
    {
      id: 'news-2',
      slug: 'biologics-campus-expansion-2000l-bioreactors',
      category: 'news',
      title: 'Lambda CDMO Expands Biologics Campus with New 2,000L Single-Use Bioreactor Suites',
      badge: 'Facility Expansion',
      date: 'February 18, 2026',
      readTime: '5 min read',
      author: {
        name: 'Facility Engineering Team',
        role: 'Ahmedabad Operations',
      },
      image: '/images/insights/bioreactor_suite_expansion.png',
      summary: 'To meet surging worldwide demand for clinical and commercial biologics manufacturing, Lambda CDMO has commissioned two additional 2,000L single-use mammalian cell culture suites.',
      keyTakeaways: [
        'Doubles overall mammalian cell culture capacity to support growing late-phase pipelines.',
        'Equipped with state-of-the-art process automation and continuous closed-system harvesting.',
        'Fully integrated with high-capacity downstream ÄKTA process skids and viral clearance systems.',
      ],
      tags: ['Expansion', '2000L Bioreactors', 'Manufacturing Capacity', 'Ahmedabad Facility'],
      detailedContent: {
        subtitle: 'Scaling up operational capacity to meet global biopharmaceutical demand',
        abstract: 'Lambda CDMO has completed the operational qualification of its Phase II facility expansion, adding two advanced 2,000L single-use bioreactor suites within its 20,000 sqm Ahmedabad biomanufacturing facility. The expansion addresses surging sponsor demand for mid-to-large-scale clinical drug substance campaigns.',
        sections: [
          {
            heading: '1. Advanced Process Architecture',
            body: [
              'The new suites incorporate single-use fluid transfer systems, automated media preparation vessels up to 5,000L, and continuous acoustic cell separation interfaces for intensified perfusion processing.',
            ],
          },
        ],
        methodologyHighlights: [
          'Cleanroom certified to ISO Class 7 (Grade C) with dedicated air handling systems.',
          'Commissioned and validated under strict ISPE baseline guide principles.',
        ],
        regulatoryImpact: 'Expands available slot capacity for 2026/2027 clinical and commercial supply agreements.',
      },
    },
    {
      id: 'news-3',
      slug: 'strategic-collaboration-next-gen-adc-cdmo',
      category: 'news',
      title: 'Strategic Collaboration Announced for Next-Generation ADC Clinical Development and Manufacturing',
      badge: 'Strategic Partnership',
      date: 'January 20, 2026',
      readTime: '4 min read',
      author: {
        name: 'Business Development Team',
        role: 'Global Alliances',
      },
      image: '/images/insights/adc_partnership.png',
      summary: 'Lambda CDMO has entered into a strategic collaboration agreement with a clinical-stage oncology biotech to provide end-to-end development, conjugation, and sterile fill-finish for a novel ADC pipeline.',
      keyTakeaways: [
        'Multi-year agreement spanning Phase I through commercialization readiness.',
        'Leverages Lambda’s high-potency containment suites and barrier isolator fill-finish.',
        'First clinical supply batch scheduled for delivery in Q3 2026.',
      ],
      tags: ['ADC', 'Partnership', 'Bioconjugation', 'Oncology', 'Clinical Supply'],
      detailedContent: {
        subtitle: 'Accelerating next-generation targeted cancer therapies into the clinic',
        abstract: 'Under the multi-year partnership, Lambda CDMO will execute cell line optimization, antibody intermediate manufacturing, cytotoxic payload conjugation, and vial fill-finish for the sponsor’s lead targeted solid-tumor oncology candidate.',
        sections: [
          {
            heading: '1. Comprehensive Program Scope',
            body: [
              'The program leverages Lambda’s integrated CDMO model, eliminating inter-vendor logistics by manufacturing the monoclonal antibody intermediate, performing linker-toxin conjugation, and conducting final aseptic fill-finish under one roof.',
            ],
          },
        ],
        methodologyHighlights: [
          'SafeBridge Category 4 high-potency containment.',
          'Custom analytical testing suite for free-payload quantification.',
        ],
        regulatoryImpact: 'Supports joint IND and IMPD submissions targeted for early 2027.',
      },
    },
    {
      id: 'news-4',
      slug: 'scientific-team-presents-pat-raman-data',
      category: 'news',
      title: 'Lambda Scientific Team Presents Breakthrough Process Analytical Technology (PAT) Data at Global Bio-Manufacturing Summit',
      badge: 'Scientific Presentation',
      date: 'January 05, 2026',
      readTime: '4 min read',
      author: {
        name: 'Scientific Affairs',
        role: 'R&D Division',
      },
      image: '/images/insights/pat_cell_monitoring.png',
      summary: 'Lead scientists from Lambda CDMO shared groundbreaking empirical results on real-time Raman spectroscopy monitoring for automated glucose and lactate control in 2,000L bioreactors.',
      keyTakeaways: [
        'Raman spectroscopy models demonstrated R² > 0.98 correlation with offline reference analyzers.',
        'Automated feed additions reduced culture lactate accumulation by 42%.',
        'Demonstrated seamless integration into distributed control systems (DCS) under GMP.',
      ],
      tags: ['PAT', 'Raman Spectroscopy', 'Bioprocessing Summit', 'Real-Time Monitoring'],
      detailedContent: {
        subtitle: 'Advancing real-time process monitoring in commercial cell culture',
        abstract: 'At the Global Bio-Manufacturing Summit, Lambda CDMO scientists unveiled peer-reviewed data demonstrating the deployment of in situ Raman probes in 2,000L mammalian cell cultures, establishing automated feedback loops that optimize critical nutrient concentrations.',
        sections: [
          {
            heading: '1. Real-Time Feedback Control Loop',
            body: [
              'By feeding multivariate calibration models directly into the automated bioreactor control skids, feed pumps adjusted dynamically, preventing nutrient depletion while maintaining minimal glucose residuals to suppress non-enzymatic glycation.',
            ],
          },
        ],
        methodologyHighlights: [
          'In situ immersion Raman probes with chemometric partial least squares (PLS) models.',
          'Inline NIR and capacitance probes for viable cell density (VCD) monitoring.',
        ],
        regulatoryImpact: 'Aligns with FDA and ICH Q8 guidelines encouraging real-time release testing and Quality-by-Design principles.',
      },
    },
    {
      id: 'news-5',
      slug: 'automated-barrier-isolator-aseptic-filling-line',
      category: 'news',
      title: 'Commissioning of Fully Automated Barrier Isolator High-Speed Aseptic Filling Line for Vials & Syringes',
      badge: 'Technology Upgrade',
      date: 'December 15, 2025',
      readTime: '5 min read',
      author: {
        name: 'Aseptic Fill-Finish Operations',
        role: 'Commercial Manufacturing',
      },
      image: '/images/insights/aseptic_filling_commissioning.webp',
      summary: 'Lambda CDMO has completed commercial validation of its high-speed automated barrier isolator filling line, accommodating nested ready-to-use (RTU) vials, syringes, and cartridges.',
      keyTakeaways: [
        'High filling speed up to 12,000 units/hour with 100% non-destructive checkweighing.',
        'Integrated automated visual inspection (AVI) system for sub-visible particulate detection.',
        'Zero human glove-port interventions required during active production runs.',
      ],
      tags: ['Aseptic Filling', 'Barrier Isolator', 'Pre-Filled Syringes', 'Commercial Packaging'],
      detailedContent: {
        subtitle: 'State-of-the-art robotic filling ensuring maximum yield and sterility assurance',
        abstract: 'The new high-speed filling line represents a quantum leap in sterility assurance. Featuring robotic de-nesting, peristaltic filling, vacuum stoppering, and automated crimp sealing within a hermetically sealed isolator, the line preserves high-value biologics with minimal line loss (<0.5%).',
        sections: [
          {
            heading: '1. Robotic Precision and Contamination Elimination',
            body: [
              'Robotic arms transfer sterile nested components without generating particulate shedding, while automated in-line scales verify fill accuracy for every single container without slowing production throughput.',
            ],
          },
        ],
        methodologyHighlights: [
          'Peristaltic filling needles engineered for zero shear on protein molecules.',
          'Automated particle detection with high-speed CMOS camera vision.',
        ],
        regulatoryImpact: 'Fully validated per EU Annex 1 guidelines and ready for global commercial batch release.',
      },
    },
  ],

  events: [
    {
      id: 'event-1',
      slug: 'global-bioprocessing-summit-2026-keynote',
      category: 'events',
      title: 'Global Bioprocessing Summit 2026: Keynote Address on Continuous Perfusion & CQA Control',
      badge: 'Keynote Presentation',
      date: 'April 22–24, 2026',
      readTime: 'Conference & Presentation',
      author: {
        name: 'Dr. Rajesh Varma',
        role: 'Head of Cell Line Development & Upstream Science',
      },
      image: '/images/insights/bioprocessing_conference_keynote.jpg',
      summary: 'Join Lambda CDMO leadership at the Global Bioprocessing Summit in Boston. Dr. Varma will deliver a keynote address detailing our continuous perfusion biomanufacturing architecture.',
      keyTakeaways: [
        'Keynote session: "Intensified Mammalian Upstream: Operating 500L Perfusion with Steady-State CQA Integrity".',
        'Live 1-on-1 partnering sessions available at Booth #412.',
        'Exclusive presentation of comparative glycosylation kinetics under steady-state perfusion.',
      ],
      tags: ['Bioprocessing Summit', 'Perfusion Culture', 'Conference', 'Boston', 'Keynote'],
      detailedContent: {
        subtitle: 'Showcasing continuous bioprocessing breakthroughs on the global stage',
        abstract: 'The Global Bioprocessing Summit brings together leaders in biopharmaceutical development. Dr. Rajesh Varma will present empirical data demonstrating continuous steady-state perfusion sustained across 30 days, yielding 2.8 g/L/day with consistent N-glycan distributions matching batch-fed controls.',
        sections: [
          {
            heading: '1. Presentation Abstract',
            body: [
              'Continuous bioprocessing promises higher volumetric productivity and reduced facility footprints. However, preventing micro-shifts in product quality over extended run times remains a hurdle.',
              'Dr. Varma presents how automated perfusion-rate adjustments tied to optical biomass sensors achieved steady-state cell densities of 60 x 10⁶ cells/mL without selective clone mutation.',
            ],
          },
          {
            heading: '2. Connect with Lambda CDMO Experts',
            body: [
              'Our executive leadership and technical team will be on-site at Booth #412 to discuss program requirements, capacity availability, and tech transfer roadmaps.',
            ],
          },
        ],
        methodologyHighlights: [
          'Alternating Tangential Flow (ATF) perfusion cell retention systems.',
          'Real-time automated bleed-and-feed control algorithms.',
        ],
        regulatoryImpact: 'Insight into regulatory frameworks governing continuous manufacturing under ICH Q13.',
      },
    },
    {
      id: 'event-2',
      slug: 'webinar-ich-q6b-analytical-comparability-biosimilars',
      category: 'events',
      title: 'Live Technical Webinar: Mastering ICH Q6B Analytical Comparability for Complex Biosimilar Filings',
      badge: 'Live Webinar',
      date: 'May 14, 2026 • 11:00 AM EST',
      readTime: '60 Min Session + Q&A',
      author: {
        name: 'Dr. Neha Patel',
        role: 'Director of Analytical Characterization',
      },
      image: '/images/insights/webinar_analytical_comparability.png',
      summary: 'An in-depth technical webinar dissecting state-of-the-art analytical comparability protocols, statistical tiering (CQAs), and agency feedback on biosimilar mAb dossiers.',
      keyTakeaways: [
        'How to establish statistical equivalence margins (Tier 1, Tier 2, Tier 3) per FDA guidelines.',
        'Resolving post-translational discrepancies between US and EU reference medicinal products.',
        'Interactive live Q&A with our senior analytical science leadership.',
      ],
      tags: ['Webinar', 'ICH Q6B', 'Biosimilars', 'Analytical Comparability', 'Regulatory Affairs'],
      detailedContent: {
        subtitle: 'Step-by-step guidance for building an unshakeable biosimilar analytical package',
        abstract: 'Regulatory approval for biosimilars hinges on the totality-of-the-evidence analytical comparability exercise. In this live interactive webinar, Dr. Neha Patel reviews real-world case studies demonstrating how to design multi-lot analytical comparability studies that pass FDA and EMA review with zero objections.',
        sections: [
          {
            heading: '1. Webinar Agenda & Key Topics',
            body: [
              '1. Structure of the comparability protocol: Sourcing reference lots across varying shelf-life ages.',
              '2. Orthogonal characterization methods: Integrating MS/MS peptide mapping, icIEF, SEC-MALS, and CD.',
              '3. Biological function: Correlating Fc receptor binding with in vitro ADCC/CDC potency assays.',
            ],
          },
        ],
        methodologyHighlights: [
          'Equivalence testing and quality range methodologies.',
          'Statistical power calculation for lot-to-lot variability analysis.',
        ],
        regulatoryImpact: 'Directly addresses FDA draft guidance on Quality Considerations for Biosimilar Products.',
      },
    },
    {
      id: 'event-3',
      slug: 'bio-europe-partnering-conference-vienna',
      category: 'events',
      title: 'Bio-Europe Partnering Conference: Meet the Lambda Executive Technical Team',
      badge: 'Partnering Forum',
      date: 'June 08–10, 2026',
      readTime: 'Partnering & Meetings',
      author: {
        name: 'Executive Leadership',
        role: 'Lambda CDMO Business Operations',
      },
      image: '/images/insights/bio_europe_atrium.jpg',
      summary: 'Lambda CDMO will attend Bio-Europe in Vienna. Schedule private 1-on-1 meetings through the partnering system to evaluate slots for 2026/2027 clinical manufacturing batches.',
      keyTakeaways: [
        'Private 1-on-1 executive discussions on pipeline development and manufacturing capacity.',
        'Confidential technical scoping for novel mAb, bispecific, and ADC clinical candidates.',
        'Review available slots in our newly qualified 2,000L bioreactor suites.',
      ],
      tags: ['Bio-Europe', 'Partnering', 'Vienna', 'Executive Meetings', 'Contract Manufacturing'],
      detailedContent: {
        subtitle: 'Strategic discussions accelerating biopharma pipeline progression',
        abstract: 'Join Lambda CDMO at Europe’s premier life sciences partnering conference. Our executive and technical teams will be conducting partnering meetings to discuss how our integrated biologics services support European and global biotechnology innovators.',
        sections: [
          {
            heading: '1. Partnering Discussion Topics',
            body: [
              'Discuss rapid tech transfer protocols for European sponsors seeking reliable clinical supply from Phase I through commercial distribution.',
            ],
          },
        ],
        methodologyHighlights: [
          'Pre-scheduled meetings via the partneringONE platform.',
        ],
        regulatoryImpact: 'Assists sponsors with Qualified Person (QP) declaration requirements for European clinical trials.',
      },
    },
    {
      id: 'event-4',
      slug: 'masterclass-high-concentration-formulation-viscosity',
      category: 'events',
      title: 'Masterclass Workshop: High-Concentration Formulation Development & Subcutaneous Viscosity Reduction',
      badge: 'Technical Workshop',
      date: 'July 16, 2026 • 2:00 PM EST',
      readTime: '90 Min Masterclass',
      author: {
        name: 'Dr. Michael Thorne',
        role: 'Senior Formulation & Lyophilization Specialist',
      },
      image: '/images/insights/formulation_masterclass.jpg',
      summary: 'A virtual masterclass focusing on overcoming high viscosity, reversible self-association, and injection force constraints in high-concentration (>150 mg/mL) biologic formulations.',
      keyTakeaways: [
        'Excipient screening strategies (amino acids, cyclodextrins, salts) for reducing solution viscosity.',
        'Glide-force and injection-force testing for auto-injectors and pre-filled syringes.',
        'Preventing opalescence and liquid-liquid phase separation (LLPS) during cold storage.',
      ],
      tags: ['Workshop', 'Formulation', 'High Concentration', 'Subcutaneous', 'Viscosity Reduction'],
      detailedContent: {
        subtitle: 'Practical biophysical strategies for patient-friendly subcutaneous injection products',
        abstract: 'Formulating therapeutic proteins at concentrations exceeding 150 mg/mL enables convenient self-administration via auto-injectors, but often leads to exponential viscosity escalation and syringe clogging. Dr. Michael Thorne presents molecular screening strategies that lower viscosity while safeguarding colloidal stability.',
        sections: [
          {
            heading: '1. Masterclass Highlights',
            body: [
              'Examine how synergistic combinations of arginine and glutamic acid interfere with hydrophobic patch-mediated self-association, reducing solution viscosity from 38 cP down to 11 cP at 180 mg/mL.',
            ],
          },
        ],
        methodologyHighlights: [
          'Microfluidic rheometry and automated dynamic light scattering (DLS).',
          'Mechanical testing of glide force in 29-gauge auto-injector needles.',
        ],
        regulatoryImpact: 'Supports FDA human factor and container-closure combination product filing expectations.',
      },
    },
    {
      id: 'event-5',
      slug: 'executive-roundtable-derisking-tech-transfer',
      category: 'events',
      title: 'Executive Roundtable: De-risking Technology Transfer & Accelerating Biologics IND Timelines',
      badge: 'Executive Roundtable',
      date: 'August 19, 2026',
      readTime: 'Invitation-Only Session',
      author: {
        name: 'Dr. Suresh Chokshi & Senior MSAT Panel',
        role: 'Manufacturing Sciences & Technology',
      },
      image: '/images/insights/tech_transfer_roundtable.png',
      summary: 'An invitation-only technical roundtable bringing together biopharma CMC leaders to examine common pitfalls in technology transfer and scale-up, and how to compress timelines safely.',
      keyTakeaways: [
        'Interactive panel discussion with CDMO process transfer engineers and regulatory strategists.',
        'Analysis of critical hand-off milestones between clone development and clinical manufacturing.',
        'Live benchmarking data comparing standard industry timelines with accelerated fast-track models.',
      ],
      tags: ['Roundtable', 'Technology Transfer', 'IND Acceleration', 'CMC Strategy', 'MSAT'],
      detailedContent: {
        subtitle: 'Peer-to-peer insights on avoiding common pitfalls in early-phase tech transfers',
        abstract: 'Moving an early-stage biologic from academic or venture labs into a cGMP manufacturing facility is fraught with scale translation traps. In this closed-door executive roundtable, senior leaders discuss risk-mitigation frameworks that ensure right-first-time execution.',
        sections: [
          {
            heading: '1. Key Discussion Themes',
            body: [
              'Raw material supply chain de-risking, media equivalence testing, single-use bag extractable profiles, and comparability assessment between development and cGMP runs.',
            ],
          },
        ],
        methodologyHighlights: [
          'FMEA (Failure Mode and Effects Analysis) applied to technology transfers.',
          'Standardized tech-transfer charter and analytical comparability templates.',
        ],
        regulatoryImpact: 'Provides actionable blueprints for de-risking critical path activities before IND submissions.',
      },
    },
  ],
};


export function getAllInsightItems(): InsightItem[] {
  return Object.values(insightsData).flat();
}

export function getInsightBySlug(category: string, slug: string): InsightItem | undefined {
  const categoryItems = insightsData[category] || [];
  return categoryItems.find((item) => item.slug === slug || item.id === slug);
}

export function getRelatedInsights(category: string, currentSlugOrId: string, limit = 3): InsightItem[] {
  const categoryItems = insightsData[category] || [];
  return categoryItems
    .filter((item) => item.slug !== currentSlugOrId && item.id !== currentSlugOrId)
    .slice(0, limit);
}
